Fresh analysis suggests that patients who stop using popular GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass at a significantly accelerated pace than those who end traditional diet and exercise plans.
Research printed in a major health publication shows that while obese people frequently drop substantial amounts of their body weight while using the jabs, the weight is regained at an average rate of 0.8 kg per month once they quit.
"Users purchasing such treatments must be informed of the danger of fast rebound weight gain when the therapy concludes," warns researcher Dr. Susan Jebb.
This pace of recovery means a return to pre-treatment weight in about 18 months.
Comparing Treatments
The analysis, which examined dozens of studies involving over 9,000 of participants, contrasted the effects of these new drugs with conventional dieting.
Scientists point out that people who lose weight through diet and exercise usually experience a less rapid weight regain—around 0.1 kg a month—once they finish.
Explaining the Quick Regain
Nutrition scientists believe the way of the jabs accounts for the amplified rebound.
The injections mimic a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.
"Artificially providing the hormone levels far above than the body's typical production could lead to the body to produce less of its endogenous GLP-1, and could diminish responsiveness to its actions," noted Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this GLP-1 'fix' means appetite is no longer kept in check, making binge eating much more probable."
A Lifelong Condition?
Health authorities advise the injections for people with obesity-related health risks, alongside prescribed lifestyle changes.
A number of clinicians contend that, given the significant potential of weight regain, the therapy is often ongoing.
This view is echoed by pharmaceutical companies, who state that the findings "emphasize the long-term character of excess weight," akin to managing diseases like high blood pressure.
Patient Accounts
Users who have stopped the jabs explain a powerful return of appetite.
"It felt as if something activating and you become ravenous," described one woman.
The struggle is exacerbated if patients have not adopted sustainable lifestyle or habit changes during treatment.
Widespread Use
Figures suggest that a significant number of people in the UK have used weight-loss jabs in the past year, with interest remaining high.
- Adoption is higher among females compared to males.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion access the drugs through private healthcare rather than the NHS.
In conclusion, researchers emphasize that while GLP-1 drugs are powerful tools for shedding pounds, they are not a standalone cure and maintained weight loss hinges on combined lifestyle support.
